EORTC-24061-HNCG

Randomized phase II feasibility study of Cetuximab combined with 4 cycles of TPF followed by platinum based chemo-radiation strategies
Study documentation
Trial StatusClosed for recruitment
DatesDate of activation: 11-Feb-08
Date Step1 close: 17-May-10
Date Step2 close: 17-May-10
Data management at EORTCFull
Phase2
Randomized trial
Type-
Targeted Sample sizeEORTC Groups: - - All Groups: 55
Number of steps2
DrugFluorouracil
Carboplatin
Cisplatin
Docetaxel
Cetuximab
Study StaffJan Bogaerts
Statistician - EORTC Headquarters, Brussels
Denis Lacombe
Coordinating Physician - , Bremen
Denis Lacombe
Coordinating Physician - EORTC Headquarters, Brussels
Type of cancerHead and Neck
Participating GroupsEORTC Head and Neck Cancer Group(Coordinating Group)
Protocol summaryClinicalTrials.gov
NCT numberNCT00646659
EudraCT2006-004189-14